Novo Nordisk A/S (NVO) Stock: Wegovy Lead Meets Long-Term Challenges

TLDR Novo stock drops 7.65% as pipeline setbacks deepen long-term growth concerns. Wegovy still supports sales, but semaglutide patent expiries approach next decade. LSEG projects Zepbound sales will exceed Wegovy by more than $7 billion in 2026. Novo may pursue more acquisitions and licensing deals to strengthen its pipeline. Zenagamtide gains attention as CagriSema setbacks [...]

The post Novo Nordisk A/S (NVO) Stock: Wegovy Lead Meets Long-Term Challenges appeared first on Blockonomi.